Peter Greenleaf currently serves as the Chief Executive Officer and member of the Board of Directors of autoimmune therapeutics company Aurinia, (NASDAQ: AUPH / TSX: AUP). Previously, Peter has served as the Chief Executive Officer of Cerecor, Inc and the CEO and Chairman of Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), where he was instrumental in its sale to Mallinckrodt PLC in 2018. Peter also served as CEO and a member of the Board of Directors of Histogenics Corporation, a regenerative medicine company.
Earlier in his career Peter served as President of Medlmmune LLC, the global biologics arm of AstraZeneca, and President of Medlmmune Ventures. He is also currently a member of the Board of Directors of Antares Pharmaceuticals, Inc. (NASDAQ: ATRS) and Chairman of the Board of Directors of Biodelivery Sciences International, Inc. (NASDAQ: BDSI). Peter earned an MBA from St. Joseph’s University and a B.S. from Western Connecticut State University.